+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

O

Actively Recruiting

Healthy Volunteer

Researchers are conducting a non-interventional, multi-site observational study to collect real-world data on the use of an autologous, hair follicle derived secretome topical cosmetic product. This product is applied following various medical aesthetic procedures to assess its effects on post-procedural erythema and recovery. The study is open-label and involves participants aged 18 to 60 undergoing specific aesthetic treatments. Participants plan to use the Acorn Autologous Hair Follicle Secretome cosmetic product as an adjunct after medical aesthetic procedures such as laser resurfacing ablative or non-ablative, Tixel treatment of the face, and treatment of acne or surgical scars combined with other procedures like microneedling or ablative laser. Some scalp treatments and Ellacor procedures are closed to enrollment. The study does not involve any experimental interventions but observes the real-world application of this topical product. During the study, participants will be monitored for symptoms and downtime after their procedures using questionnaires over 1 to 7 days post-treatment. Researchers will collect data on post-procedure symptoms and recovery time to evaluate the products impact. The total study period extends until February 2027, with ongoing assessments at specified intervals to capture real-world outcomes and safety information.

Age: 18Years +All Genders
42 locations
P

Actively Recruiting

Researchers are evaluating the safety of the IC-8 Apthera intraocular lens IOL after treatment for posterior capsular opacification PCO, a common complication following IC-8 Apthera IOL implantation. This prospective, multi-center, non-randomized study focuses on patients who have already received the IC-8 Apthera IOL and now require NdYAG laser capsulotomy for PCO. The study aims to verify post-market safety following training in a standardized laser treatment technique. Participants previously implanted with the IC-8 Apthera IOL and experiencing PCO will be treated with NdYAG laser capsulotomy using a sponsor-recommended method. There is one study group, and subjects will be followed for 24 months after their IC-8 Apthera IOL implantation. The study includes about six visits over this two-year period to monitor safety and treatment outcomes. During the study, participants will undergo assessments of laser treatment outcomes, any complications, and IOL-related evaluations. Researchers will track additional laser treatments, secondary surgical interventions, ocular and serious adverse events, and subjective visual disturbances using specific questionnaires. The study lasts for two years post-implantation, with regular visits to ensure thorough monitoring of participant eye health and treatment effects.

Age: 22Years +All Genders
14 locations
C

Actively Recruiting

This research aims to evaluate the safety and effectiveness of the smaller incision, new generation implantable miniature telescope SING-IMT in patients aged 65 and older who have moderate to severe central vision loss caused by late-stage age-related macular degeneration AMD. The study focuses on individuals with vision impairment due to geographic atrophy or disciform scars affecting the central retina, conditions related to advanced AMD. Participants who qualify will undergo implantation of the SING-IMT device during routine cataract surgery. The device consists of two micro lenses within a glass tube mounted on a flexible silicone carrier and is inserted through an approximately 6.5 mm incision using a proprietary delivery system. After implantation, patients will attend five follow-up visits over about 12 months and may receive up to 12 rehabilitation or training sessions with a low vision specialist to help adapt to the device. Throughout the study, participants will have their best-corrected distance and near visual acuity checked, including tests with and without refraction and with an external telescope simulator to assess potential benefit. Researchers will monitor safety and effectiveness outcomes approximately 12 months post-surgery, including measurements of visual acuity, anterior chamber depth, device positioning, adverse events, and posterior capsule opacification. The total study involvement lasts about one year following surgery, with ongoing assessments and rehabilitation support.

Age: 65Years +All GendersPhase Not Applicable
10 locations
S

Actively Recruiting

This research evaluates patients with metastatic HER-2-positive breast cancer who are at risk of heart damage from trastuzumab-based treatments. It includes two groups one observational group of patients taking beta blockers, ACE inhibitors, or ARBs alongside their cancer therapy, and a smaller randomized group studying whether carvedilol may prevent heart side effects from chemotherapy. The study aims to understand how often heart problems occur and identify factors that predict these risks. Participants are assigned to one of three groups those taking carvedilol twice daily, those receiving no additional treatment, and those already on beta blockers, ARBs, or ACE inhibitors who are observed without intervention. Treatments or observation continue for up to 108 weeks, with repeated cycles every 12 weeks unless disease progresses or side effects occur. The study also collects blood samples and performs heart function imaging to explore biomarkers and measure heart strain. During the study, participants undergo regular echocardiograms every 12 weeks to assess heart function and strain. Researchers monitor for cardiac events, interruptions in cancer therapy, and adherence to medication. Blood samples are taken to bank for future studies. The main outcome is time until the first sign of cardiac dysfunction over about two years. Safety and side effects of treatments are also tracked, and participants are followed until the study ends in 2031.

Age: 18Years +All GendersPhase 3
590 locations